从医学脆弱儿童中分离的呼吸道合胞病毒分离株的分子与表型特征:一项尼塞韦单抗的2/3期随机双盲帕利珠单抗对照试验(MEDLEY)的探索性分析
MEDLEY试验在早产和/或患先天性心脏病或早产儿慢性肺病的婴儿中比较尼塞韦单抗与帕利珠单抗。对25例确诊呼吸道合胞病毒感染者的分离株测序显示,尼塞韦单抗结合位点替换未影响尼塞韦单抗的中和活性。
要点
- 试验共观察到25例确诊呼吸道合胞病毒感染并完成测序。
- 呼吸道合胞病毒A型分离株中未检测到尼塞韦单抗结合位点替换。
- 尼塞韦单抗中和了所有来自MEDLEY参与者的A型和B型分离株的结合位点替换。
核心结论
- MEDLEY试验中检测到的结合位点替换均未影响呼吸道合胞病毒对尼塞韦单抗中和作用的敏感性。
研究设计与样本
- MEDLEY为随机、帕利珠单抗对照的2/3期试验,纳入早产和/或患先天性心脏病或早产儿慢性肺病的婴儿。
- 第1赛季参与者按2:1随机接受单剂尼塞韦单抗(体重<5 kg为50 mg,体重≥5 kg为100 mg)后每月安慰剂共4剂,或帕利珠单抗每月一次共5剂(每剂15 mg/kg体重)。
- 第2赛季参与者继续尼塞韦单抗和安慰剂(尼塞韦单抗/尼塞韦单抗),或按1:1重新随机换用尼塞韦单抗(帕利珠单抗/尼塞韦单抗)或继续帕利珠单抗(帕利珠单抗/帕利珠单抗);第2赛季尼塞韦单抗剂量为200 mg。
- 通过集中检测因呼吸系统疾病就医参与者的鼻拭子识别呼吸道合胞病毒感染病例。
- 通过微量中和试验评估尼塞韦单抗和帕利珠单抗结合位点替换。
主要发现
- 试验期间观察到25例确诊呼吸道合胞病毒感染并完成测序:第1赛季尼塞韦单抗组12例、帕利珠单抗组10例,第2赛季每组各1例。
- 呼吸道合胞病毒A型分离株(n=14)的分子测序未检测到尼塞韦单抗结合位点替换,检测到3个帕利珠单抗中和抵抗性替换(Lys272Met、Lys272Thr、Ser275Leu)。
- 呼吸道合胞病毒B型分离株(n=11)中检测到的抗呼吸道合胞病毒单克隆抗体结合位点替换仅为尼塞韦单抗结合位点Ile206Met:Gln209Arg和Ile206Met:Gln209Arg:Ser211Asn。
- 尼塞韦单抗中和了MEDLEY参与者中分离的呼吸道合胞病毒A型和B型分离株中的所有尼塞韦单抗和帕利珠单抗结合位点替换。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nirsevimab is an extended half-life monoclonal antibody (mAb) licensed for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease in neonates, infants and medically vulnerable children. We characterized RSV isolates recovered from participants enrolled in MEDLEY: a randomized, palivizumab-controlled phase 2/3 trial of nirsevimab in infants born preterm and/or with congenital heart disease or chronic lung disease of prematurity. METHODS: Participants were assessed in two RSV seasons (Season 1 and 2). Season 1 participants were randomized (2:1) to receive a single dose of nirsevimab (50 mg if weight <5 kg or 100 mg if weight ≥5 kg in Season 1; 200 mg in Season 2) followed by four monthly doses of placebo, or five once-monthly doses of palivizumab (15 mg/kg weight per dose). Season 2 participants continued nirsevimab and placebo (nirsevimab/nirsevimab) or were re-randomized (1:1) to switch to nirsevimab (palivizumab/nirsevimab) or continue palivizumab (palivizumab/palivizumab). Cases of RSV infection were identified by central testing of nasal swabs from participants seeking medical attention for respiratory illnesses. Nirsevimab and palivizumab binding site substitutions were assessed via microneutralization assay. RESULTS: Twenty-five cases of confirmed RSV infection were observed during the trial and sequenced: 12 in nirsevimab recipients and 10 in palivizumab recipients during Season 1, and 1 case in each Season 2 group. Molecular sequencing of RSV A (n = 14) isolates detected no nirsevimab binding site substitutions, and 3 palivizumab neutralization-resistant substitutions (Lys272Met, Lys272Thr, Ser275Leu). The nirsevimab binding site Ile206Met:Gln209Arg and Ile206Met:Gln209Arg:Ser211Asn substitutions were the only anti-RSV mAb binding site substitutions detected among RSV B isolates (n = 11). Nirsevimab neutralized all nirsevimab and palivizumab binding site substitutions in RSV A and B isolates recovered from MEDLEY participants. CONCLUSION: No binding site substitution detected during MEDLEY affected RSV susceptibility to nirsevimab neutralization.
引用
- Tuffy KM, Ahani B, Domachowske JB, et al. Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY). Vaccine. 2024. PMID: 39241352. doi:10.1016/j.vaccine.2024.126276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。